Bernstein initiates Getinge stock coverage with Market Perform rating

Bernstein SocGen Group initiated coverage on Getinge AB (GETIB:SS) with a Market Perform rating and a price target of SEK228.00. The firm highlights Getinge's leading position in hospital equipment for acute and intensive care, representing a significant portion of the company's revenue and adjusted EBITDA, as well as its strong market share in sterilization and prevention of contamination. Getinge's key instruments include ECMO and Paragonix, both within its acute and intensive care division.

Analysis

Bernstein SocGen Group has initiated coverage on Getinge AB (GETIB:SS) with a "Market Perform" rating and a SEK228.00 price target, signifying a neutral outlook on the Swedish medical technology firm. Getinge's primary strength lies in its acute and intensive care division, which is a global leader in hospital equipment and instruments, contributing 52% of total revenues and a significant 64% of adjusted EBITDA; key products within this segment include ECMO and Paragonix. The company also maintains a strong market presence through its Surgical Workflow division, specializing in sterilization and contamination prevention, which accounts for 35% of FY24 revenue, 24% of adjusted EBITDA, and commands market shares between 20% and 45%. The Life Sciences division, manufacturing equipment for biomanufacturers, contributes 13% of sales and 12% of revenues. Bernstein's initiation provides enhanced visibility, though the "Market Perform" rating suggests the current share price largely reflects the company's established market positions and near-term growth prospects without significant immediate upside.

Key Decisions for Investors

• Investors should consider the "Market Perform" rating as an indication that Getinge's stock may be fairly valued, suggesting a neutral stance or hold strategy at current levels.
• Evaluate the significant revenue and EBITDA contribution from the acute and intensive care division (52% and 64% respectively) as both a core strength and a potential concentration risk.
• Monitor growth and innovation within the Surgical Workflow and Life Sciences divisions, as these segments could offer diversification and future upside potential for Getinge.